BC Week In Review | Jul 18, 2016
Clinical News

Aggrastat tirofiban regulatory update

FDA issued a complete response letter to Medicure for an sNDA for Aggrastat tirofiban to treat patients with ST-segment elevation myocardial infarction (STEMI). Medicure said the agency asked for additional information; the company did not...
BioCentury | Jan 11, 2016
Finance

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year....
BC Week In Review | Oct 19, 2015
Company News

Cardiome, Mitsubishi Tanabe Pharma deal

Cardiome and Mitsubishi’s Mitsubishi Pharma Europe Ltd. subsidiary partnered to co-promote Cardiome’s Aggrastat tirofiban and Mitsubishi’s Exembol argatroban in the U.K. for a three-year term. Each company will promote the other company’s product to the...
BC Week In Review | Oct 5, 2015
Company News

Cardiome, Eddingpharm deal

Cardiome’s Correvio International S.a.r.l. subsidiary granted Eddingpharm exclusive rights to commercialize Aggrastat tirofiban in China. The non-peptide integrin alpha(2b)beta(3) ( GPIIb/IIIa ; CD41/CD61 ) antagonist is indicated to reduce the rate of thrombotic cardiovascular events in patients...
BC Week In Review | Sep 21, 2015
Clinical News

Aggrastat tirofiban regulatory update

Medicure submitted an sNDA to FDA for Aggrastat tirofiban to treat patients with ST segment elevation myocardial infarction (MI). The company expects a PDUFA date in July 2016. The non-peptide integrin alpha(2b)beta(3) ( GPIIb/IIIa ; CD41/CD61...
BC Week In Review | Aug 17, 2015
Clinical News

Aggrastat tirofiban regulatory update

Cardiome submitted an sNDS to Health Canada for Aggrastat tirofiban to reduce major cardiovascular events in patients with acute myocardial infarction (AMI) intended for primary percutaneous coronary intervention (PCI). The sNDS also seeks to include...
BC Week In Review | May 4, 2015
Clinical News

Aggrastat tirofiban regulatory update

FDA approved a label revision for cardiovascular drug Aggrastat tirofiban from Medicure to amend the dosing time for the 25 ug/kg high-dose bolus regimen to “within 5 minutes” from “over 3 minutes” in patients with...
BC Week In Review | Jun 2, 2014
Company News

AOP Orphan, Cardiome deal

Cardiome granted AOP Orphan rights to market Aggrastat tirofiban in Austria, Hungary, Switzerland and other Eastern European territories. The non-peptide integrin alpha(2b)beta(3) ( GPIIb/IIIa ; CD41/CD61 ) antagonist is approved in the U.S. and EU to treat...
BC Week In Review | Apr 21, 2014
Company News

Knight Therapeutics, Medicure cardiovascular news

Medicure hired Knight as an advisor to advance the company's U.S. specialty pharmaceutical business and "corporate development initiatives." Medicure has rights from Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.) to Aggrastat tirofiban in the...
BC Extra | Feb 21, 2014
Financial News

Cardiome raises C$15 million in follow-on

Cardiome Pharma Corp. (TSX:COM; NASDAQ:CRME) raised C$15 million ($13.7 million) through the sale of 1.5 million shares at C$10 in a follow-on underwritten by Canaccord and other undisclosed banks. Shareholder CarCor Investment Holdings raised C$15...
Items per page:
1 - 10 of 88